{"entity":{"id":"nct07580339","kind":"trial","name":"Combining DCSZ11 With Radiation and Chemotherapy as Neoadjuvant Treatment for pMMR Locally Advanced Rectal Cancer","aka":[],"tldr":"A phase 2 trial of capecitabine and fOLFOX (5-FU, leucovorin, oxaliplatin) in colorectal cancer, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, not yet recruiting.","summary":"Combining DCSZ11 With Radiation and Chemotherapy as Neoadjuvant Treatment for pMMR Locally Advanced Rectal Cancer is a phase 2, interventional study registered as NCT07580339 by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, with a registry enrolment figure of 30 participants, started 2026-10 and due to reach its primary completion in 2030-10. Interventions recorded: DCSZ11; Radiation; Capecitabine; Oxaliplatin. Conditions listed: Rectal Cancer. Primary outcome: Composite Complete Response (compCR) Rate; Number of participants experiencing a drug-related toxicity requiring treatment discontinuation. Colorectal eligibility wording from the registry: \"* Rectal cancer (with tumor tissue present at or below the peritoneal reflection) as determined by MRI pelvis or endoscopic ultrasound\". Sites: United States. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07580339","url":"https://clinicaltrials.gov/study/NCT07580339"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer","msi-high-colorectal"],"sections":[],"technologies":["cytotoxic-chemotherapy","platinum"],"targets":[],"drugs":["capecitabine","folfox"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07580339","phase":"2","setting":"Combining CD93 Inhibition (DCSZ11) With Short Course Radiation and Chemotherapy as Part of Total Neoadjuvant Treatment (TNT) for High-risk Mismatch Repair Proficient (pMMR) Locally Advanced Rectal Cancer (LARC)","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","enrolled":30,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07580339/","neighbours":{"cancer":[{"id":"msi-high-colorectal","kind":"cancer","name":"Mismatch-repair deficient (MSI-high) colorectal cancer","route":"/cancers/msi-high-colorectal/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"}],"drug":[{"id":"capecitabine","kind":"drug","name":"Capecitabine","route":"/drugs/capecitabine/"},{"id":"folfox","kind":"drug","name":"FOLFOX (5-FU, leucovorin, oxaliplatin)","route":"/drugs/folfox/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}